Compare Charles River Laboratories Intl. Inc (CRL) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Procter & Gamble Co — how do they compare? Charles River Laboratories Intl. Inc trades at $228.74 (market cap $11.14B), while Procter & Gamble Co trades at $147.83 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 30.5× Charles River Laboratories Intl. Inc's market cap, and Procter & Gamble Co pays a 2.92% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PG | |
|---|---|---|
Market Cap | $11.14B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $167.18 |
52-Week Low | $145.57 | $138.10 |
Enterprise Value | $14.00B | $365.64B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Procter & Gamble (PG) trades at $147.58, down 0.53% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 beating expectations of $1.56, and robust cash flow generation. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for May 2026 payment.
PG offers stable dividend income with 69 consecutive years of increases but faces premium valuation concerns amid modest growth outlook. Analyst consensus targets $161.71 with 54% buy ratings, though near-term upside may be limited by competitive pressures and economic sensitivity. The stock presents a defensive play with execution risks in maintaining margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
